Hyperkalemia | Current Treatment | EU5 | 2016
Hyperkalemia is an important complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD) with significant impacts on morbidity and mortality. Management of hyperkalemia is dependent on both patient symptoms and the elevation of serum potassium levels, and it typically involve potassium binders to control potassium levels in the body. These potassium binders have a significant side-effect profile; therefore, tolerable and effective treatments are needed. This content provides an in-depth examination of the different treatment and prescribing practices for hyperkalemia within Europe and offers insights for companies seeking to enter this market.
Related Market Assessment Reports
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
Report
Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (US)
Male hypogonadism (low testosterone, or low T) is a condition characterized by impaired spermatogenesis and low serum testosterone. Most cases are secondary, driven by aging or comorbidities (e.g…
